All News

The FDA approval of Roche/Genentech's breast cancer drug T-DM1 (brand name Kadcyla) last week has caused a mixed reaction from healthcare analysts.

The Choosing Wisely campaign, an initiative of the American Board of Internal Medicine, is focused on encouraging physicians, patients, and other healthcare stakeholders to think and talk about medical tests and procedures that may be unnecessary, and in some instances can cause harm. Just this week, the leaders behind this initiative added a number of do's and don'ts to their growing list.